

Donald L Lamm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3285921/publications.pdf>

Version: 2024-02-01

37
papers

5,894
citations

218381

26
h-index

377514

34
g-index

39
all docs

39
docs citations

39
times ranked

3606
citing authors

#	ARTICLE	IF	CITATIONS
1	MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY. <i>Journal of Urology</i> , 2000, 163, 1124-1129.	0.2	1,075
2	Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials. <i>Journal of Urology</i> , 2002, 168, 1964-1970.	0.2	1,055
3	A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette-Guérin for Transitional-Cell Carcinoma of the Bladder. <i>New England Journal of Medicine</i> , 1991, 325, 1205-1209.	13.9	577
4	Management of stage T1 tumors of the bladder: International Consensus Panel. <i>Urology</i> , 2005, 66, 108-125.	0.5	371
5	Use of a New Tumor Marker, Urinary NMP22, in the Detection of Occult or Rapidly Recurring Transitional Cell Carcinoma of the Urinary Tract Following Surgical Treatment. <i>Journal of Urology</i> , 1996, 156, 363-367.	0.2	303
6	Bacillus Calmette-guerin Immunotherapy of Superficial Bladder Cancer. <i>Journal of Urology</i> , 1980, 124, 38-42.	0.2	282
7	Definitions, End Points, and Clinical Trial Designs for Non-muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. <i>Journal of Clinical Oncology</i> , 2016, 34, 1935-1944.	0.8	279
8	A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer Group. <i>Journal of Urology</i> , 2011, 186, 2158-2167.	0.2	247
9	Megadose Vitamins in Bladder Cancer: A Double-Blind Clinical Trial. <i>Journal of Urology</i> , 1994, 151, 21-26.	0.2	161
10	An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 440-447.	0.8	140
11	Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. <i>Nature Reviews Urology</i> , 2015, 12, 225-235.	1.9	139
12	Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1995, 1, 119-126.	0.8	124
13	BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. <i>Nature Reviews Urology</i> , 2017, 14, 244-255.	1.9	108
14	Bacillus Calmette-Guérin With or Without Interferon γ -2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2010, 184, 1915-1919.	0.2	107
15	Defining Progression in Nonmuscle Invasive Bladder Cancer: It is Time for a New, Standard Definition. <i>Journal of Urology</i> , 2014, 191, 20-27.	0.2	98
16	Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy-Associated Adverse Events. <i>European Urology Supplements</i> , 2008, 7, 667-674.	0.1	87
17	Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). <i>BJU International</i> . 2013. 112. 742-750.	1.3	87
18	Immunotherapy of Murine Transitional Cell Carcinoma. <i>Journal of Urology</i> , 1982, 128, 1104-1108.	0.2	85

#	ARTICLE	IF	CITATIONS
19	Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2014, 192, 305-315.	0.2	82
20	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. , 2017, 5, 68.		68
21	Bladder cancer, 1996. Ca-A Cancer Journal for Clinicians, 1996, 46, 93-112.	157.7	65
22	Keyhole Limpet Hemocyanin Immunotherapy of Bladder Cancer: Laboratory and Clinical Studies. European Urology, 2000, 37, 41-44.	0.9	56
23	Superficial Bladder Cancer Therapy. Scientific World Journal, The, 2004, 4, 387-399.	0.8	44
24	Long Term Protection in Bladder Cancer Following Intralesional Immunotherapy. Journal of Urology, 1984, 132, 570-573.	0.2	40
25	Interferon alfa in the treatment paradigm for nonâ€“muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 35.e21-35.e30.	0.8	40
26	Riskâ€“adapted management of lowâ€“grade bladder tumours: recommendations from the International Bladder Cancer Groupâ€“(IBCG). BJU International, 2020, 125, 497-505.	1.3	31
27	Clinical Practice Recommendations for the Management of Nonâ€“Muscle Invasive Bladder Cancer. European Urology Supplements, 2008, 7, 651-666.	0.1	28
28	Maintenance Bacillus Calmette-GuÃ©rin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Nonâ€“Muscle-Invasive Bladder Cancer. European Urology Supplements, 2010, 9, 715-734.	0.1	25
29	A Randomized Prospective Comparison of Oral Versus Intravesical and Percutaneous Bacillus Calmette-guerin for Superficial Bladder Cancer. Journal of Urology, 1990, 144, 65-67.	0.2	22
30	A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment. Vaccine, 2021, 39, 7308-7318.	1.7	19
31	Improving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression in Superficial Bladder Cancer. European Urology Supplements, 2006, 5, 654-659.	0.1	14
32	Pelvic recurrence after radical cystectomy: a call to arms. BJU International, 2015, 116, 172-173.	1.3	10
33	Tumor implantation: a rare but potentially preventable cause of death in cystectomy patients. Canadian Journal of Urology, 2010, 17, 5216-8.	0.0	6
34	Re: Per-Uno MalmstrÃ¶m, Richard J. Sylvester, David E. Crawford, et al. An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-GuÃ©rin for Nonâ€“Muscle-Invasive Bladder Cancer. Eur Urol 2009;56:247â€“56. European Urology, 2010, 57, e7-e9.	0.9	2
35	Editorial Comment. Urology, 2011, 78, 854-855.	0.5	0
36	IMPACT OF SMOKING ON OUTCOMES AFTER INTRAVESICAL BACILLUS CALMETTEâ€“GUÃ©RIN THERAPY FOR UROTHELIAL CARCINOMA NOT INVADING MUSCLE OF THE BLADDER. BJU International, 2011, 108, 530-530.	1.3	0

#	ARTICLE	IF	CITATIONS
37	Re: Richard J. Sylvester, Willem Oosterlinck, Sten Holmang, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2015.05.050 . <i>European Urology</i> , 2015, 68, e127.	0.9	0